4547:TYO
Kissei Pharmaceutical Co Ltd
3 700,00 JP¥
0,00%
(0,00) 1D
2 қаз., 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Mkt. cap
172,21 млрд
Avg. vol.
68,01 мың
Volume
0,00
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 мың
Mkt. cap
172,21 млрд
Avg. vol.
68,01 мың
Volume
0,00
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 мың
News stories
From web sources and news partners
Proactive financial news
·
38 минут бұрын
Nova Minerals to host investor webinar on Estelle and US antimony strategy
Simply Wall Street
·
45 минут бұрын
EasySource Marketplace Listing Might Change The Case For Investing In Paylocity (PCTY)
TipRanks
·
39 минут бұрын
News Corp Updates US$1 Billion Share Repurchase Program for Nasdaq-Listed Stock
USA Today
·
14 сағат бұрын
Is a stock market correction coming? Most Americans think so
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 мың
Founded1946 ж. 09 там.
HeadquartersMatsumoto, Nagano, Жапония
SectorPharmaceutical industry
Websitekissei.co.jp